Shots: The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R2) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone […]readmore
Tags : Treated
Shots: The US FDA has accepted sBLA and granted BT designation for the dual regimen to treat patients with advanced HCC prior treated with sorafenib. The sBLA ha also received […]readmore
Shots: The NOC is based on the positive data of Calquence in ACE-LY-004 trial demonstrating 81% OR rate for patients with relapsed or refractory MCL The Health Canada approval of Calquence […]readmore
Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into […]readmore
Regulatory
Exelixis’ Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular
Shots: The approval is based on P-III CELESTIAL study results assessing Cabometyx (60 mg, qd) vs PBO in 760 patients in a ratio (2:1) with 2L advanced HCC who previously […]readmore